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Abstract DNA methylation can contribute to the stable tran-
scriptional silencing of mammalian genes. Often times, these
genes are important developmental regulators, and their silenc-
ing in cell types where they are not supposed to be active is
important for the phenotypic stability of the cells. To identify
key developmental regulator genes whose expression in termi-
nally diﬀerentiated cells may be inhibited by DNA methylation,
mouse dermal ﬁbroblasts were demethylated with 5-aza-2 0-
deoxycytidine, and changes in gene expression monitored by
microarray analysis. Endothelin-1 (Et1 or Edn1), which en-
codes a cytokine with diverse regulatory functions, was among
the genes upregulated following demethylation. We found that
CpG dinucleotides within a short region in intron 1 of the gene
have dramatically higher levels of methylation in Et1-non-
expressing ﬁbroblasts and chondrocytes as compared to the
Et1-expressing mouse cell line, mIMCD-3. Strong evolutionary
conservation of this region implies its role in the cis-regulation
of Et1 transcription. To conﬁrm that should Et1 in dermal
ﬁbroblasts become aberrantly activated, it could indeed lead
to the dysregulation of many downstream genes, we exposed
ﬁbroblasts to exogenous ET1 peptide and assayed for transcrip-
tional changes by microarray. ET1 treatment resulted in signif-
icant expression changes – primarily downregulation – of a
signiﬁcant number of genes. In particular, Tgfb2 and Tgfb3
were among the downregulated genes, which in turn alter the
expression status of their many target genes. These data sug-
gest that the stable silencing of Et1 through its associated
DNA methylation in intron 1 is critical for the developmental
stability of dermal ﬁbroblasts, and perhaps other cell types as
well.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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1. Introduction
The stability of gene expression in diﬀerentiated cells is
essential for the proper functioning of multicellular organisms.
In particular, diﬀerentiated cells must prevent the mis-expres-
sion of genes that regulate many other genes or they risk det-
rimental trans- or de-diﬀerentiation. One such key regulatory
gene is Et1, which encodes a cytokine with a wide range of reg-
ulatory functions. ET1 has been shown to modulate cell prolif-
eration [1,2], extracellular matrix composition [3], ﬁbrosis in
wound repair response [4], and vascular tone [5]. ET1 also
has important developmental functions, playing a key part in
several organogenic processes such as cardiogenesis [6,7],
osteogenesis [8], vasculogenesis [9], and neural crest develop-
ment [10].
The regulatory eﬀects of ET1 are conducted through its two
G protein-coupled receptors – ETA and ETB. These receptors
are present on the surfaces of many cell types, including dermal
ﬁbroblasts, making them potentially responsive to ET1 in both
an autocrine and paracrine fashion [11]. Under normal condi-
tions, however, dermal ﬁbroblasts do not express ET1 them-
selves.
Given the signiﬁcant impact of ET1 on the development
and physiology of a wide variety of cells, it is reasonable to
suppose the expression of Et1 must be precisely regulated
such that it becomes active only in the right cell types and
at the right times. The mechanism for the transcriptional acti-
vation of Et1 has been well studied. A mouse Et1 genomic
region containing 6-kb sequence upstream of transcription
start site along with the ﬁrst exon and ﬁrst intron was suﬃ-
cient to confer endothelium-speciﬁc expression [12]. Within
this region, many transcription factor binding sites have been
identiﬁed. For example, activation of Et1 requires the recruit-
ment of GATA-2 and AP1 [13]. Additionally, enhancer
elements have been identiﬁed that are important for cell
type-speciﬁc Et1 activation [14]. However, mechanistic insight
into the transcriptional silencing of Et1 in non-expressing
cells is lacking.
The silencing of key regulatory genes such as myogenin and
Oct4 in terminally diﬀerentiated cells has been attributed, at
least in part, to DNA methylation of localized regions of the
genes [15–18]. By analogy, methylation may also contribute
to the silencing of Et1 in terminally diﬀerentiated, non-express-
ing cells.
Here, we identiﬁed Et1 as a gene upregulated following
drug-induced demethylation of mouse dermal ﬁbroblasts.
Further analysis showed that a short region in intron 1 of
Et1 has signiﬁcantly elevated levels of methylation in non-
expressing ﬁbroblasts and chondrocytes as compared to an
Et1-expressing cell line. Exposure of dermal ﬁbroblasts to
exogenous ET1 peptide altered the expression of a signiﬁcant
number of genes, indicating that the proper silencing of Et1 is
important in maintaining the phenotypic stability of ﬁbro-
blasts.
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2. Results
2.1. Demethylation and microarray analysis
Primary mouse dermal ﬁbroblasts were treated with 5-aza-
2 0-deoxycytidine (5A2dC) to demethylate the genome (see Sec-
tion 4). Three separate ﬁbroblast derivations from genetically
identical litters were performed to generate three biological
replicates. Each biological replicate was then split into an
experimental sample treated with 5A2dC and a control sample
not treated with the drug. These 6 samples were each subjected
to transcriptional microarray analysis using Aﬀymetrix chips
(see Section 4). The data from the demethylation experiment
have been deposited in NCBIs Gene Expression Omnibus
(GEO, http://www.ncbi.nlm.nih.gov/geo/) and are accessible
through GEO Series Accession No. GSE4696.
We focused on genes upregulated following 5A2dC treat-
ment because they may represent genes silenced by methyla-
tion. Genes with signiﬁcant expression changes were
identiﬁed by the t test as having at least a 2-fold expression dif-
ference between experimental and control samples with
P < 0.05 across the three biological replicates, as is convention-
ally done for such microarray studies. This led to 352 upregu-
lated genes, of which, some were conﬁrmed using quantitative
RT-PCR analysis (see Section 4). Some of these genes were of
unknown biological function. Many contained repetitive ele-
ments, which is expected because repetitive elements are fre-
quently silenced by methylation [19,20]. The remaining genes
span a wide range of functional categories without obvious
enrichment for any particular category.
We were particularly interested in key regulatory genes that
became activated by demethylation, and Et1 was one gene that
ﬁt this description. Expression levels of Et1 were checked
through quantitative RT-PCR, conﬁrming the microarray re-
sult of an approximately 8-fold upregulation in ﬁbroblasts
upon 5A2dC treatment (Fig. 1A). To place into context the ex-
tent to whichEt1 was activated following demethylation, the
expression level of Et1 was compared between 5A2dC-treated
ﬁbroblasts and the inner medullary collecting duct cells
(mIMCD-3), a line that normally expresses Et1. The expres-
sion level of Et1 was approximately equal between them. This
suggests that Et1 expression in dermal ﬁbroblasts reaches
physiological levels following demethylation.
We expanded the assay of Et1 activation to another non-
expressing cell type, primary mouse chondrocytes. These cells
were likewise treated with 5A2dC to demethylate the genome.
Quantitative RT-PCR of Et1 in 5A2dC-treated versus control
cells indicated an upregulation of approximately 3-fold
(Fig. 1B). 5A2dC-treated chondrocytes have an approximately
2-fold lower Et1 expression as compared to mIMCD-3 cells,
indicating that the level of activation is perhaps lower than
physiological levels. The diﬀerence between chondrocytes and
ﬁbroblasts in their response to demethylation may stem from
diﬀerences in transcription factor milieu or the extent of
drug-induced demethylation between these two cell types.
2.2. Identifying methylated region of Et1 in ﬁbroblasts
The activation of Et1 in dermal ﬁbroblasts following treat-
ment of the demethylating drug implies a role for DNA meth-
ylation in the regulation of the gene. To determine the
methylation pattern of Et1 in detail, ﬁbroblast genomic
DNA was treated with sodium bisulﬁte to convert unmethy-
lated cytosine to thymine, followed by PCR ampliﬁcation.
The ampliﬁed product was cloned into plasmid, and for each
amplicon, a large number of clones were sequenced to quantify
the level of methylation at individual CpG sites. We identiﬁed
a canonical CpG island using the CPGIE software [21], which
is located from 492 to 9 bp relative to the translational start
site. The region was ampliﬁed in two segments. The ﬁrst covers
547 to 189 bp with 23 CpG sites (amplicon 2). We se-
quenced 28 clones, which revealed only 2 CpG sites with just
1 methylated clone each (Fig. 2). The second segment goes
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Fig. 1. Comparing Et1 expression levels between diﬀerent cell popu-
lations by quantitative RT-PCR. (A) Et1 expression in ﬁbroblasts.
Fold diﬀerence in expression level is given for three comparisons:
between mIMCD-3 cells and ﬁbroblasts not treated with 5A2dC;
between ﬁbroblasts treated with 5A2dC and ﬁbroblasts not treated
with 5A2dC; and between mIMCD-3 cells and ﬁbroblasts treated with
5A2dC. (B) Et1 expression in chondrocytes. The three comparisons are
the same as in (A) except chondrocytes are used instead of ﬁbroblasts.
For each comparison, standard error from three replicates is indicated,
and the asterisk denotes P < 0.025 by t test.
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from 158 to +36 bp with 9 CpG sites (amplicon 3). Again,
out of 40 clones sequenced, only 2 CpG sites had a single meth-
ylated clone each (Fig. 2). There are 9 CpG sites located just
upstream of the computer-predicted CpG island. We ampliﬁed
the region from 897 to 664 bp covering these CpG sites
(amplicon 1), and found a similar lack of methylation (Fig. 2).
Whereas the methylation of canonical CpG islands has been
associated with the silencing of X-inactivated and imprinted
genes, methylation within more circumscribed pockets that
sometimes lie outside of CpG islands has been associated with
the silencing of certain developmental genes [15–18]. Such
methylation may target speciﬁc cis-regulatory elements impor-
tant for transcription factor binding. Cross-species conserva-
tion in non-coding regions is often used to identify putative
cis-regulatory sequences. To examine whether regions outside
of the CpG island of Et1may contain additional cis-regulatory
sequences, we obtained a conservation plot of Et1 across four
mammalian species: mouse, rat, human and dog (Fig. 2). It re-
vealed a highly conserved sequence element among the species
within intron 1, suggesting that this element may have regula-
tory functions. We used bisulﬁte sequencing to investigate the
methylation status of the region around this conserved ele-
ment, dividing the region into two PCR fragments (amplicons
4 and 5). Amplicon 4 spans +70 to +382 bp and contained 11
CpG sites. In the 42 clones sequenced, 7 of the 11 CpG sites
had 20–40% of the clones methylated (Fig. 2). Amplicon 5 cov-
ers +397 to +861 bp with 15 CpG sites, and encompasses the
highly conserved sequence element. In the 31 clones sequenced,
all CpG sites had between 20% and 60% of the clones methyl-
ated (Fig. 2). Thus, there is signiﬁcantly more methylation in
amplicons 4 and 5 than in the rest of the gene analyzed
(P < 0.0001 with Bonferroni correction). Three nearly consec-
utive CpG sites located from +856 to +862 bp within amplicon
5 were methylated in the most number of clones, all with more
than 50% of the clones methylated. Each of these three sites
has signiﬁcantly more methylation than the remaining CpG
sites analyzed (P < 0.0001 with Bonferroni correction). These
CpG sites correspond to a putative Sp1 transcription factor
binding site. If Sp1 binding indeed occurs at the site and is re-
quired for Et1 expression, methylation may block its binding
and therefore contribute to the silencing of Et1.
As a control, ﬁbroblasts treated with 5A2dC (with activated
Et1 expression) were also subjected to bisulﬁte sequencing. In
amplicons 4 and 5, methylation levels were substantially re-
duced in treated ﬁbroblasts as compared to untreated ﬁbro-
blasts (Fig. 3E). For amplicon 5, which contains the highly
conserved regulatory element, the average fraction of methyl-
ated clones for a given CpG site in untreated ﬁbroblasts is
36%, but is reduced to 12.6% in 5A2dC-treated ﬁbroblasts.
This strong reduction in methylation provides a clear link be-
tween demethylation of intron 1 and expression of Et1 in ﬁbro-
blasts.
2.3. Methylation analysis of Et1 in additional cell types
Chondrocytes, which do not normally express Et1, also dem-
onstrated an upregulation of Et1 expression following drug-
induced demethylation. If methylation in intron 1 of Et1 in-
deed contributes to the gene silencing in ﬁbroblasts, then the
same mechanism may also be at work to silence Et1 expression
in chondrocytes. We performed bisulﬁte sequencing on chon-
drocyte genomic DNA focusing on amplicons 4 and 5. For
amplicon 4, six of the 11 CpG sites had between 16% and
40% of the sequenced clones methylated (Fig. 3C). For ampli-
con 5, all 15 CpG sites had between 17% and 57% of the clones
methylated (Fig. 3C). This pattern is very similar to that
observed in ﬁbroblasts (Fig. 3B), and is consistent with the
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Fig. 2. DNA methylation status of Et1 as assayed by bisulﬁte sequencing. Top half of the ﬁgure depicts the region of Et1 from 897 to +861 bp,
covering 5 0 UTR to intron 1. It was divided into 5 amplicons, each separately ampliﬁed, cloned into plasmid, and sequenced for multiple clones.
Circles represent CpG sites, and all the circles connected by a horizontal line were sequenced within the same clone. Filled circle denotes methylation
at that site, whereas open circle denotes lack of methylation. The putative CpG island of the gene is indicated. Bottom half of the ﬁgure is a plot
depicting the conservation of the region across multiple mammalian species (generated through the UCSC Genome Browser), with dark lines
indicating conservation.
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idea that methylation of this region may contribute to the
silencing of Et1 expression.
We next examined the methylation status of this region in
mIMCD-3 cells. If methylation of the region indeed inhibits
Et1 expression, then it should not be methylated in the Et1-
expressing mIMCD-3 cells. Bisulﬁte sequencing of mIMCD-3
genomic DNA showed a complete lack of methylation among
the 25 clones of amplicon 4 examined, and methylation at only
2 of the 13 CpG sites in amplicon 5 (Fig. 3D). The lack of
clone-to-clone variation in methylation pattern is expected
given that mIMCD-3 is a cell line. Collectively, these data
show a correlation between methylation within intron 1 of
Et1 and transcriptional silencing of the gene.
2.4. ET1 treatment and microarray analysis
DNA methylation has been associated with the stable silenc-
ing of genes. If dermal ﬁbroblasts indeed utilize methylation to
silence Et1, it may be because aberrant activation of Et1 can
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signiﬁcantly alter cellular phenotype and have a profound im-
pact on the expression of many downstream genes. Fibroblasts
themselves express ETA and ETB, receptors for the ET1 pep-
tide, and are therefore expected to respond to ET1 in an auto-
crine manner. Hence mis-expression of Et1 in ﬁbroblasts may
indeed alter the expression of many genes in these cells. To test
this, ﬁbroblasts were treated with synthetic ET1 peptide. Fol-
lowing the exposure, ET1-treated cells were compared to un-
treated cells by transcriptional microarray with 3 biological
replicates each for treated and control samples (the data from
the ET1 treatment experiment have been deposited in GEO
with Accession No. GSE4695). Using the criteria of 2-fold or
higher expression change and a P-value less than 0.05, we
found 22 upregulated and 72 downregulated genes (Supple-
mentary Tables S1 and S2). A subset of both upregulated
and downregulated genes were conﬁrmed by quantitative
RT-PCR (data not shown).
The results of ET1 treatment were compared with the results
of 5A2dC treatment to identify genes that were upregulated or
downregulated in both data sets. Of the upregulated genes, 3
were shared in both experiments, accounting for 16% of the
upregulated genes in the ET1 experiment and <1% of the
upregulated genes in the 5A2dC experiment (Supplementary
Table S1). Of the downregulated genes, 22 were shared be-
tween the two experiments, accounting for 30% of the down-
regulated genes in the ET1 experiment and 16% of the
downregulated genes in the 5A2dC experiment (Supplemen-
tary Table S2). Apparently, a signiﬁcant fraction of ET1-
responsive genes – far larger than random chance (Fisher’s
exact test, P < 0.0001 with Bonferroni correction) – is also
responsive to 5A2dC. This argues that some of the genes that
respond to 5A2dC may do so as a secondary consequence of
Et1 activation by 5A2dC treatment.
Also of note, there are signiﬁcantly more downregulated
genes shared between 5A2dC treated and Et1 treated samples
than upregulated genes (Fisher’s exact test, P < 0.0001). Et1
therefore may act as a potent transcriptional inhibitor in der-
mal ﬁbroblasts. Activation of Et1 due to demethylation results
in additional genes being aﬀected, primarily downregulated, in
5A2dC treated cells. Many of the genes downregulated in der-
mal ﬁbroblasts following ET1 exposure are targets of the
TGFb pathway, including extracellular matrix components
and signal transduction pathway components. The likely cause
of TGFb pathway inhibition is the resultant downregulation of
the Tgfb2 and Tgfb3 genes following ET1 exposure. The ET1
signaling pathway may directly inhibit Tgfb2 and Tgfb3, or it
may also aﬀect the expression of transcriptional regulator(s) of
Tgfb2 and Tgfb3. However, no known direct transcriptional
regulator of Tgfb2 or Tgfb3 was identiﬁed as either upregu-
lated or downregulated by ET1 treatment, raising the possibil-
ity that the ET1 pathway is a direct inhibitor of Tgfb2 and
Tgfb3 expression.
3. Discussion
DNA methylation is an epigenetic modiﬁcation frequently
associated with the stable silencing of genes in mammalian
genomes. Demethylation by artiﬁcial means such as 5A2dC
treatment can activate many genes, some of which are the di-
rect consequence of demethylation in cis-regulatory regions
of the aﬀected genes. In this study, we identiﬁed Et1 as one
of the genes activated in mouse dermal ﬁbroblasts following
demethylation by 5A2dC. We further showed that a short re-
gion in intron 1 of this gene was methylated in the Et1-non-
expressing ﬁbroblasts and chondrocytes, but not in the
Et1-expressing cell line mIMCD-3. In other studies, it has been
shown that decreased Et1 expression in human carcinoma cell
lines LK-2 and EBC-1 is associated with hypermethylation of a
short region in intron 1 that roughly corresponds to the meth-
ylated region we identiﬁed in mouse ﬁbroblasts and chondro-
cytes [22]. These results provide evidence for, though they do
not yet deﬁnitively prove, the role of intron 1 methylation in
the silencing of Et1 expression.
If methylation indeed contributes to Et1 silencing, one pos-
sible mechanism may involve the blocking of Sp1 transcription
factor binding. The region in intron 1 that has the maximum
level of methylation in Et1-non-expressing cells corresponds
to an Sp1 binding site. This region is also highly conserved
across many divergent species, further supporting its cis-regu-
latory function. It has been shown in other genes that binding
of Sp1 can be inhibited through methylation of its binding site,
thus inhibiting transcription [23–25]. We therefore postulate
that the inhibition of Et1 in ﬁbroblasts and chondrocytes
may involve targeted methylation of the Sp1 binding site
(among other sites) in intron 1, which block Sp1 binding and
contribute to Et1 silencing.
To better understand the impact of ET1 action on cells that
do not normally produce this cytokine, we exposed dermal
ﬁbroblasts to exogenous ET1 and used transcriptional micro-
array to analyze global changes in gene expression. We found
upregulation and, more commonly, downregulation of a sig-
niﬁcant number of genes, consistent with the notion that the
ET1 pathway can serve to both inhibit and activate of genes
[3]. We found that Tgfb2 and Tgfb3 were downregulated along
with their downstream target genes, especially genes involved
in extracellular matrix formation, cell mobility, and cell adhe-
sion [26,27]. The ET1 and the TGFb signaling pathways have
previously been associated with each other in several contexts
[11,28–30], but it has not yet been demonstrated that the ET1
pathway can directly inhibit Tgfb2 and Tgfb3 expression. Our
results raise the possibility that the ET1 pathway may have a
direct inhibitory eﬀect on the expression of Tgfb2 and Tgfb3.
ET1 is a critical, multi-functional cytokine involved in a wide
variety of developmental and physiological processes. It may
therefore be essential to tightly regulate the expression of Et1
such that it is active only in the right cell types at the right
times. One mechanism of such tight regulation, at least in the
context of transcriptional silencing, could be DNA methyla-
tion. Results reported here are consistent with the model that
in Et1-non-expressing cells, silencing of the gene may involve
methylation of the intron 1 region, which in turn may result
in blocking Sp1 transcription factor binding at the methylated
site. We also provided suggestive evidence that the ET1 path-
way may directly inhibit the expression of Tgfb2 and Tgfb3.
4. Materials and methods
4.1. Cell culture
Dermal ﬁbroblasts were obtained from explant cultures of 1–3 day
neonatal mice using procedures as previously described [31]. Cultures
were maintained in Dulbecco’s modiﬁed Eagle’s medium (DMEM;
Invitrogen; Carlsbad, CA, USA) with L-glutamine and high glucose
plus 10% FBS (Invitrogen) and 100 U/mL penicillin streptomycin
4564 T.W. Vallender, B.T. Lahn / FEBS Letters 580 (2006) 4560–4566
(Invitrogen) at 37 C and 5% CO2. Cells were passaged at conﬂuence
by 0.25% trypsin EDTA (Invitrogen). Chondrocytes were obtained
from digestion of neonatal mouse ventral rib cage. Soft tissue was elim-
inated through digestion in 0.25% collagenase II (Invitrogen) in 0.25%
trypsin EDTA (Invitrogen) for 1 h at 37 C. Chondrocytes were re-
leased by incubation in 0.25% collagenase II (Invitrogen) in PBS (Invit-
rogen) for 1 h at 37 C. Cultures were maintained in DMEM with L-
glutamine and high glucose (Invitrogen) plus 10% heat-inactivated
FBS (Invitrogen) and 100 U/mL penicillin streptomycin (Invitrogen)
at 37 C and passaged at conﬂuence by 0.25% trypsin EDTA (Invitro-
gen). Et1 expressing inner medullary collecting duct cell line mIMCD-3
(CRL-2123; ATCC; Manassas, VA, USA) was grown according to
ATCC speciﬁcations [32]. Brieﬂy, growth medium was a 1:1 mixture
of DMEM and Ham’s F12 medium containing 1.2 g/L sodium bicar-
bonate, 2.5 mM L-glutamine, 15 mM HEPES and 0.5 mM sodium
pyruvate (Invitrogen) plus 10% FBS (Invitrogen) and 100 U/mL peni-
cillin streptomycin (Invitrogen) at 37 C and 5% CO2. Cells were pas-
saged at conﬂuence by 0.25% trypsin EDTA (Invitrogen).
4.2. 5-Aza-20-deoxycytidine and Et1 treatment
Freshly prepared 5A2dC (Sigma; St. Louis, MO, USA) stock solu-
tion was diluted in growth medium to a concentration of 5 lM. A
new preparation of the drug in growth medium was added every
24 h for a total of 96-h drug exposure. Cells were grown in normal
medium following treatment for an additional 24 h. Freshly prepared
synthetic human, porcine Et1 peptide (Sigma) was added to dermal
ﬁbroblast growth medium at 100 nM for 24 h.
4.3. RNA preparation and quantitative RT-PCR
Total RNA was isolated from cells using RNeasy mini columns
(Qiagen; Valencia, CA, USA) and treated with RNAse-free DNAse I
(Invitrogen). RNA integrity and purity were conﬁrmed using a spectro-
photometer and Agilent 2100 Bioanalyzer (Agilent Technologies; Palo
Alto, CA, USA). For quantitative RT-PCR, cDNA was generated
using SuperScript III First-Strand Synthesis System for RT-PCR
(Invitrogen). iQ SYBR Green supermix (Bio-Rad; Hercules,
CA, USA) was used to quantify transcript levels with GAPDH ampli-
ﬁcation to normalize the samples. A melt curve at the end of the ampli-
ﬁcation was performed to check for product speciﬁcity. Samples were
run in triplicate using the iCycler iQ system (Bio-Rad) and analyzed
with Beacon Designer 2.0 software (Biosoft International; Palo Alto,
CA, USA).
4.4. Gene expression analysis
Samples were prepared using standard Aﬀymetrix protocols.
Brieﬂy, double-stranded cDNA was generated using 5 lg total RNA
with the GeneChip One-Cycle cDNA Synthesis kit (Aﬀymetrix;
Santa Clara, CA, USA). Biotin-labeled cRNA was synthesized with
the GeneChip IVT Labeling kit (Aﬀymetrix). Both cDNA and
cRNA cleanup and cRNA fragmentation were performed with Gene-
Chip Sample Cleanup Module (Aﬀymetrix). Fragmented cRNA
samples were hybridized to GeneChipMouse Genome 430 2.0 Array
(Aﬀymetrix). The University of Chicago Functional Genomics Facility
performed sample hybridization, labeling, and scanning.
4.5. Statistical analysis
Three biological replicates were created to provide appropriate sta-
tistical power for data analysis in each microarray experiment. DNA
Chip Analyzer (dChip) [33] was used to analyze microarray data. Sam-
ples were visually inspected and any scratches or imperfections were
excluded. PM and MM probes were normalized to median probe
intensity using the invariant set method. Model-based expression in-
dexes were calculated with the PM–MMmodel. Probes with no present
call in any of the samples were ﬁltered out as unreliable. Upregulated
and downregulated genes were identiﬁed as having a minimum 2-fold
change in expression and a maximum P-value of 0.05 by t test.
4.6. CpG island identiﬁcation
The CpG island for Et1 was identiﬁed using CpG Island Explorer
software [21]. The criteria for CpG island identiﬁcation were a mini-
mum 50% GC content and 0.60 CpG observed/expected within a
500 bp length. The identiﬁed CpG island is located from 711 to
+164 relative to the translational start site.
4.7. Bisulﬁte sequencing
Genomic DNA was puriﬁed from cells as described [34]. Genomic
DNA was digested with restriction enzymes (without recognition sites
in the ampliﬁed region) to aid in denaturation prior to bisulﬁte treat-
ment. The EZ DNA Methylation Kit (Zymo Research; Orange,
CA, USA) was used for bisulﬁte treatment, desulfonation, and desalt-
ing of genomic DNA. Primers and PCR conditions are listed in Sup-
plementary Table S1. PCR-ampliﬁed products were cloned using
TOPO TA Cloning Kit with pCR2.1-TOPO (Invitrogen) and
transfected into One Shot TOP10 chemically competent E.coli cells
(Invitrogen). PCR products of individual clones were sequenced using
DYEnamic ET dye terminator (GE Healthcare Life Sciences; Piscat-
away, NJ, USA) on an Applied Biosystems 3730 DNA Analyzer (Ap-
plied Biosystems; Foster City, CA, USA). Sequence ﬁles were
examined using Sequencher software (Gene Codes Corp.; Ann
Arbor, MI, USA). At least 25 clones were sequenced for each region
of interest to appropriately gauge methylation levels.
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at doi:10.1016/j.febslet.2006.07.017.
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